We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TLC:ASXLottery Corporation Limited Analysis

Data as of 2026-05-19 - not real-time

A$5.33

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The Lottery Corporation Limited trades at a price of $5.33, well above its DCF‑derived fair value of roughly $2.16, implying a significant overvaluation. Valuation multiples are extreme – a PE of ~33x, PB of ~35x and a dividend yield of 3% supported by a payout ratio just over 100%, raising concerns about dividend sustainability. Technicals are bearish: the stock sits below its 20‑, 50‑ and 200‑day SMAs, MACD shows a bearish signal and RSI hovers near neutral, with support around $5.08 and resistance near $5.71.
On the positive side, the company secured a 40‑year extension of its Victorian lottery licence, dramatically reducing regulatory uncertainty and underpinning long‑term cash flow stability. Despite a modest 2% revenue growth, margins remain strong (gross >95%, operating ~17%). Volatility is elevated at ~23% over 30 days, but beta is essentially flat, indicating limited market‑wide systematic risk. Overall, the stock appears overvalued with short‑term downside pressure, yet it benefits from a secure licensing position and solid cash generation for patient investors.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish technical momentum (price below SMAs, negative MACD)
  • Significant overvaluation relative to DCF and multiples
  • Dividend payout ratio exceeding earnings

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • 40‑year licence extension securing revenue base
  • Strong operating cash flow and high margins
  • Continued valuation pressure but stable earnings

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Long‑term regulatory certainty from licence extension
  • Robust cash generation supporting potential dividend adjustments
  • Expectation of price convergence toward intrinsic value

Key Metrics & Analysis

Financial Health

Revenue Growth2.00%
Profit Margin9.59%
P/E Ratio33.3
ROE113.95%
ROA9.02%
Debt/Equity744.49
P/B Ratio34.8
Op. Cash FlowA$617.1M
Free Cash FlowA$474.8M

Technical Analysis

TrendBearish
RSI46.4
SupportA$5.08
ResistanceA$5.71
MA 20A$5.40
MA 50A$5.43
MA 200A$5.45
MACDBearish
VolumeIncreasing
Fear & Greed Index89.07

Valuation

Fair ValueA$2.16
Target PriceA$5.83
Upside/Downside9.33%
GradeOvervalued
TypeValue
Dividend Yield3.00%

Risk Assessment

Beta-0.04
Volatility22.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.